Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances: Proceedings of the Second International Conference on Malignant Lymp

ISBN-13: 9781461296324 / Angielski / Miękka / 2011 / 669 str.

Franco Cavalli; Gianni Bonadonna;Marcel Rozencweig

Opis

Malignant lymphomas remain a fascinating research topic for clinicians as well as basic scientists. Rapidly increasing technical sophistication, ex panded knowledge and broader implications of new findings underline the need for a forum to integrate the latest developments in the multiple areas involved in the challenging study of lymphoid malignancies. This volume includes contributions of renowned experts and is based on a selection of papers presented at the Second International Conference on Malignant Lymphomas that was held in Lugano, Switzerland, in June 1984. Updated information is provided on various experimental fields including cell biolo gy, immunology, genetics and cell biochemistry. Particular attention has been given to special clinical entities such as the lymphomas associated with the Acquired Immune Deficiency Syndrome. Recent advances in the treat of Hodgkin's disease, ncin-Hodgkin's lymphomas and childhood lym ment phomas are highlighted with emphasis on growing experience with new therapeutic approaches including monoclonal antibodies and bone marrow transplantation. The contents of the volume reflect and translate numerous avenues of exploration. While there might be some unavoidable overlap, most appear essentially complementary. The intent of the Program Committee of the Second International Conference on Malignant Lymphomas was to promote further interactions between all those who are devoting major efforts to elucidate the nature of these diseases or their optimal therapy. This volume will hopefully amplify this objective. The Editors wish to thank the contributors for delivering the manuscripts on schedule."

Spis treści

I. Immunopathology.- 1. The cell of origin of Hodgkin’s disease.- 2. Hodgkin’s disease: Further information derived from cell lines.- 3. Origin and biologic function of Reed-Sternberg cells.- 4. Immunologic phenotypes of non-Hodgkin’s lymphomas: Correlation with morphology and function.- 5. Non-Hodgkin’s lymphoma with multilobated nuclei is not a distinct pathologic entity.- 6. Burkitt’s lymphoma: Multiparametric analysis of 55 cell lines with special reference to morphometry.- 7. Regulation of T-cell colony formation in the absence of added growth factors, in patients with T-cell malignancies.- II. Cytogenetics.- 1. Banded chromosome abnormalities in non-Hodgkin’s lymphoma. Correlations with morphology, immunologic phenotype and clinical course.- 2. Chromosomal aberrations in leukemic low-grade malignant B-cell lymphoproliferative neoplasias.- 3. Chromosome abnormalities in Burkitt lymphoma and Burkitt-type acute lymphoblastic leukemia.- 4. DNA content and proliferation in non-Hodgkin’s lymphoma: Flow cytofluorometric DNA analysis in relation to the Kiel classification.- 5. Oncogenes in human neoplasms.- 6. Stage specific transforming genes in lymphoid neoplasms.- III. Biochemical markers.- 1. DNA synthetic and degradative pathways in malignant lymphomas.- 2. Enzymes involved in adenosine metabolism in normal or leukemic lymphocytes.- 3. Purine metabolism in normal and pathologic lymphoid cell differentation.- 4. Purine degradative enzymes in the malignant cells of patients with B-cell leukemia.- 5. Lymphocyte uroporphyrinogen synthase activity as a diagnostic test in lymphoproliferative disorders — preliminary results.- 6. Enzymatic and ultrastructural properties of the plasma membrane in human leukemias, in non-Hodgkin’s lymphomas and in human lymphoblastoid cells.- IV. Clinico-pathologic correlations.- 1. Prognostic significance of cytologic subdivision in nodular sclerosing Hodgkin’s disease: An analysis of 1156 patients.- 2. Comparison of the Working Formulation of non-Hodgkin’s lymphoma with the Rappaport, the Kiel, and the Lukes-Collins Classifications. Correlations and prognostic value.- 3. Bone marrow and blood involvement by non-Hodgkin’s lymphoma: Clinicopathologic features and prognostic significance in relationship to the Working Formulation.- 4. Clonal blood B-cell excess in relation to prognosis in untreated non-leukemic patients with non-Hodgkin’s lymphoma (NHL).- 5. Patterns of survival in advanced non-Hodgkin’s lymphoma.- V. Special clinical entities.- 1. Acquired Immune Deficiency Syndrome (AIDS): Basic findings.- 2. Malignant lymphoma in homosexual men: Relationship to Acquired Immune Deficiency Syndrome (AIDS).- 3. Unusual presentations of non-Hodgkin’s lymphomas in homosexual males.- 4. Immunoproliferative small intestinal disease.- VI. Treatment of Hodgkin’s disease.- 1. The current status of the Stanford randomized clinical trials of the management of Hodgkin’s disease.- 2. The current status of NCI trials in Hodgkin’s disease.- 3. Current status of the Milan trials for Hodgkin’s disease in adults.- 4. Indications for combined modality therapy in patients with Hodgkin’s disease.- 5. Combined modality treatment of Hodgkin’s disease confined to lymph nodes. Results 14 years later.- 6. Treatment of early stage Hodgkin’s disease: A randomized trial of radiotherapy plus chemotherapy versus chemotherapy alone.- 7. Randomized study of chemotherapy alone vs. chemotherapy plus radiotherapy in Clinical Stages IA-IIA Hodgkin’s Disease.- 8. Chemotherapy alone versus combined modality therapy for Stage III Hodgkin’s disease: A five-year follow-up of a Southwest Oncology Group study (SWOG-7518) USA.- 9. Chemotherapy plus radiotherapy in clinical Stages IA to IIIB Hodgkin’s disease. Results of the H 77 trial (1977-1980).- 10. Surgical restaging after 3 or 6 courses of MOPP chemotherapy in Hodgkin’s disease.- 11. Staging laparotomy with splenectomy in Stage I and II Hodgkin’s disease. No therapeutic benefit.- 12. Comparison of initial splectomy and spleen irradiation in clinical Stages I and II Hodgkin’s disease.- 13. Prognostic groups for management of clinically localized Hodgkin’s disease.- 14. Management of localized, infradiaphragmatic Hodgkin’s disease: Experience of a rare clinical presentation at St. Bartholomew’s Hospital.- 15. Chemotherapy (MVPP) for Stage IIB/IV Hodgkin’s disease with an assessment of prognostic factors.- 16. Incidence of liver involvement and correlation of biopsy results with Ann Arbor clinical criteria and response to chemotherapy in advanced Hodgkin’s disease: A Southwest Oncology Group study.- 17. Second cancers after treatment in two successive cohorts of patients with early stages of Hodgkin’s disease.- 18. Late complications of cytotoxic chemotherapy given for advanced Hodgkin’s disease.- VII. Treatment of non-Hodgkin’s lymphomas.- 1. Overview on current strategy of the treatment of non-Hodgkin’s lymphomas.- 2. The low grade non-Hodgkin’s lymphomas: Current approaches to therapy.- 3. Treatment of diffuse large cell non-Hodgkin’s lymphomas.- 4. The use of chemotherapy for localized large cell lymphoma Results from the University of Arizona.- 5. A randomized comparison of two chemotherapy regimes: BACOP vs COPP in the treatment of diffuse histiocytic and mixed lymphoma.- 6. Results of ifosfamide-Etoposide combinations for patients with recurrent or refractory aggressive lymphoma.- 7. New Agents for Hodgkin’s and non-Hodgkin’s lymphomas.- 8. Autologous stem cell transplant for poor prognosis lymphoma.- 9. In vitro purging with 4-hydroperoxycyclophosphamide and its effects on the hematopoietic and stromal elements of human bone marrow.- 10. Treatment of refractory non-Hodgkin’s lymphoma with intensive chemo-radiotherapy and autologous bone marrow transplantation.- 11. Transplantation with anti-B1 monoclonal antibody and complement treated autologous bone marrow for relapsed B-cell non-Hodgkin’s lymphoma.- 12. The immunobiology of B-cell lymphoma. Studies with anti-idiotype antibodies.- 13. Therapeutic use of monoclonal anti-idiotype antibodies against B-cell lymphoma.- 14. Radioimmunodetection of human B-cell lymphomas with a radiolabeled tumor-specific monoclonal antibody (Lym-1).- 15. Treatment of cutaneous T-cell lymphomas with biologic response modifiers: Recombinant leukocyte A interferon and T101 monoclonal antibody.- 16. Clinical interferon (IFN) studies in leukemia and lymphoma.- VIII. Treatment of childhood lymphomas.- 1. Current status of the curability of children with Hodgkin’s disease: An assessment of the risk: benefit ratio of modern therapy.- 2. Treatment of childhood Stages I and II Hodgkin’s disease without radiotherapy.- 3. Combined modality treatment with reduced chemotherapy and radiotherapy, and selective splenectomy, in children with Hodgkin’s disease.- 4. Strategies for management of childhood non-Hodgkin’s lymphomas based upon stage and immunopathologic subtype; Rationale and current results.- 5. BFM trials for childhood non-Hodgkin’s lymphomas.- 6. Characteristics and results of treatment of non-Hodgkin’s lymphoma in young people — Experience of the Pediatric Branch, NCI, USA.

O autorze

Franco Cavalli, geboren 1942, ist Chefarzt fur Onkologie in Bellinzona und Professor an den Universitäten Bern und Varese. 1989 grundete er die internationale Fachzeitschrift Annals of Oncology (hrsg. von der Universität Oxford), die er zehn Jahre lang als Chefredaktor fuhrte. Cavalli hat zahlreiche internationale Auszeichnungen erhalten, darunter den Ehrenpreis der North Down Development Organization (NDDO). Er war Präsident der Krebsliga Schweiz, seit 2003 ist er wissenschaftlicher Direktor des Onkologischen Instituts der italienischsprachigen Schweiz (IOSI) in Bellinzona, 2006 wurde er Präsident der Internationalen Krebs-Union (UICC). Er ist einer der renommiertesten Krebsforscher in Europa. Zudem ist er Mitbegrunder der Organisation fur Medizinische Hilfe fur Zentralamerika und hat mehrere Projekte in Nicaragua, El Salvador, Guatemala und Mexiko initiiert. Cavalli ist auch politisch aktiv, er war Fraktionschef der SP im Bundesparlament in Bern.